The DOI matches its Crossref record.
Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial
Open accessAbstract
OBJECTIVE: To assess long-term safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: Patients completing FTY720 Research Evaluating Effects of Daily Oral Therapy in MS (FREEDOMS) were eligible for this dose-blinded, parallel-group extension study, continuing fingolimod 0.5 mg/day or 1.25 mg/day, or switching from placebo to either dose, randomized 1:1. Efficacy variables included annualized relapse rate (ARR), brain volume loss (BVL), and confirmed disability progression (CDP). Between-group analyses were conducted in the intent-to-treat (ITT) population from FREEDOMS baseline to end of study. Within-group analyses compared years 0-2 (FREEDOMS) and years 2-4 (extension) in the extension ITT population. RESULTS: Of 1,272 patients (FREEDOMS ITT population), 1,033 were eligible, and 920 enrolled in the extension study (continuous-fingolimod: 0.5 mg [n = 331], 1.25 mg [n = 289]; placebo-fingolimod: 0.5 mg [n = 155], 1.25 mg [n = 145]); 916 formed the extension ITT population (n = 330; n = 287; n = 154; n = 145) and 773 (84%) completed. In the continuous-fingolimod groups, ARR was lower (p < 0.0001), BVL was reduced (p < 0.05), and proportionately more patients were free from 3-month CDP (p < 0.05) than in a group comprising all placebo-fingolimod patients. Within each placebo-fingolimod group, ARR was lower (p < 0.001, both) and BVL was reduced after switching (p < 0.01, placebo-fingolimod 0.5 mg). Rates and types of adverse events were similar across groups; no new safety issues were reported. CONCLUSION: Efficacy benefits of fingolimod during FREEDOMS were sustained during the extension; ARR and BVL were reduced after switching. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that long-term fingolimod treatment is well-tolerated and reduces relapse rates, disability progression, and MRI effects in patients with RRMS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Montalban, X., Gold, R., Thompson, A. J., Otero-Romero, S., Amato, M. P., Chandraratna, D., Clanet, M., Comi, G., Derfuss, T., Fazekas, F., et al. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458517751049 · Cited by 712
Self-citationTiming of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
He, A., Merkel, B., Brown, J. W. L., Zhovits Ryerson, L., Kister, I., Malpas, C. B., Sharmin, S., Horakova, D., Kubala Havrdova, E., Spelman, T., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30067-3 · Cited by 465
Brain health: time matters in multiple sclerosis
Giovannoni, G., Butzkueven, H., Dhib-Jalbut, S., Hobart, J., Kobelt, G., Pepper, G., Sormani, M. P., Thalheim, C., Traboulsee, A., & Vollmer, T. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.07.003 · Cited by 458
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings
Coles, A. J., Cohen, J. A., Fox, E. J., Giovannoni, G., Hartung, H.-P., Havrdova, E., Schippling, S., Selmaj, K. W., Traboulsee, A., Compston, D. A. S., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004354 · Cited by 277
Self-citationChun, J., Kihara, Y., Jonnalagadda, D., & Blaho, V. A. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021358 · Cited by 131
Metadata
- Authors
- Kappos, L., O'Connor, P., Radue, E.-W., Polman, C., Hohlfeld, R., Selmaj, K., Ritter, S., Schlosshauer, R., von Rosenstiel, P., Zhang-Auberson, L., & Francis, G.
- Venue
- Neurology
- Published
- 2015-04-14
- Volume
- 84
- Issue
- 15
- Pages
- 1582-1591
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2159712156
- Cited by
- 189
- References
- 0
- FWCI
- 17.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. https://app.cochat.ai/papers/10.1212/wnl.0000000000001462
- The paper
- Kappos, L., O'Connor, P., Radue, E.-W., Polman, C., Hohlfeld, R., Selmaj, K., Ritter, S., Schlosshauer, R., von Rosenstiel, P., Zhang-Auberson, L., & Francis, G. (2015). Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology. https://doi.org/10.1212/wnl.0000000000001462
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.